To hear about similar clinical trials, please enter your email below
Trial Title:
Registry Study of Chinese Patients With Marginal Zone Lymphoma (MOTIVE)
NCT ID:
NCT06534463
Condition:
Marginal Zone Lymphoma
Conditions: Official terms:
Lymphoma
Lymphoma, B-Cell, Marginal Zone
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
Description:
The dosage and duration of any drug in this study will be determined by the physician
based on local clinical practice and local drug labels. The drugs in this study include,
but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and
Lenalidomide. In this non-interventional study, all treatment drug usage will be
determined by the physician based on clinical practice and/or the respective drug labels
in China.
Arm group label:
Observational Cohort
Summary:
This study aims to evaluate real-world treatment modalities and their corresponding
effectiveness and safety in Chinese patients with marginal zone lymphoma, while also
exploratively analyzing patient characteristics and health-related quality of life.
Criteria for eligibility:
Study pop:
Participants who are about to undergo marginal zone lymphoma(MZL) treatment (i.e., those
who have been recommended for and intend to receive MZL treatment at the time of signing
the informed consent form)
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Be diagnosed as MZL
- Meet the treatment indications for MZL
Exclusion Criteria:
- Any reason that, in the investigator's opinion, makes the participant unsuitable to
participate in this study.
Gender:
All
Minimum age:
14 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
September 1, 2024
Completion date:
September 1, 2029
Lead sponsor:
Agency:
Ruijin Hospital
Agency class:
Other
Source:
Ruijin Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06534463
